THE ACTIVATION OF NICOTINIC RECEPTORS IMPAIRS THE RESPONSE OF TRIPLE NEGATIVE BREAST CANCER CELLS TO PACLITAXEL

SALEM , A; CLOZZA M; JUCHANI MAMANI Z; SALES M; OBREGON J; PANIAGUA V; ALEJANDRO ESPAÑOL

Mar del Plata

Congreso; Reunión Anual de Sociedades de Biociencias 2019; 2019

SAIC-SAFE-SAB-SAP

We previously demonstrated the role of cholinergic receptors in tumor progression. Particularly, muscarinic receptors are expressed in different types of breast tumors and are absent in normal mammary cells. The presence of the agonist carbachol enhances the effect of conventional chemotherapeutic agents in the treatment of these tumors. The expression of nicotinic acetylcholine receptors (nAChRs) has also been reported in these same tumors and in non-tumorigenic mammary cells. Since the consumption of nicotine (NIC) in smokers promotes the progression of lung cancer, we analyzed the effect of NIC in different types of human breast tumors by measuring cell viability with the MTT reagent and the modulation that NIC exerts on the response of these cells to the cytotoxic agent paclitaxel (PX). Treatment with added NIC for 48 h increased the proliferation of breast cells in a concentration-dependent manner. The maximal effect (Emax) obtained was significant with respect to control without treatment in different types of tumor cells (MCF-7: 111 ± 9; MDA-MB231: 89 ± 2; and MDA-MB468: 44 ± 5 %; p